IL-2 Mutein and Anti-PD-1 Combination for Selective Tumor Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved combination therapies for cancer treatment, including combinations of IL-2 superagonists with anti-PD-1 antibodies, oncolytic viruses, or CAR-T cells to enhance immune activation and overcome immunosuppressive tumor microenvironments.
Innovation Solution
Development of IL-2 muteins with specific amino acid substitutions, such as L80F, R81D, L85V, I86V, and I92F, combined with anti-PD-1 antibodies, and the use of modified oncolytic viruses to target immunosuppressive cells in the tumor microenvironment, enhancing immune cell activation and tumor targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IL-2 superagonists with enhanced IL-2Rβ binding affinity are developed, then immune cell activation is improved, but CD25 binding affinity increases leading to reduced selectivity and potential toxicity
Solution Approach 1:
The patent applies local quality by making specific amino acid substitutions at particular positions (L80F, R81D, L85V, I86V, I92F) in the IL-2 superagonist molecule. These localized changes selectively enhance binding affinity for IL-2Rβ while reducing affinity for CD25, creating different binding characteristics at different interaction sites. This allows the molecule to have high efficacy through strong IL-2Rβ binding while minimizing toxicity by having reduced CD25 binding.
2Reliability
If combination therapy with anti-PD-1 antibodies is implemented, then tumor targeting is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges two distinct therapeutic approaches by combining IL-2 superagonists with anti-PD-1 antibodies in a coordinated treatment regimen. The IL-2 superagonist component activates and expands T cells and NK cells, while the anti-PD-1 antibody component removes inhibitory signals on these immune cells. This combination creates a synergistic effect where both agents work together to enhance anti-tumor immunity, with the IL-2 superagonist providing immune cell expansion and the anti-PD-1 antibody providing immune cell activation through checkpoint inhibition.
3Reliability
If amino acid substitutions are made to enhance IL-2Rβ binding, then binding affinity is improved, but molecular stability may be affected
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at positions 80, 81, 85, 86, and 92 of the IL-2 superagonist molecule. Each substitution (L80F, R81D, L85V, I86V, I92F) is designed to optimize binding parameters - specifically enhancing affinity for IL-2Rβ while maintaining or improving overall protein stability. The cumulative effect of these parameter changes at multiple positions creates a molecule with superior binding characteristics without compromising structural integrity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy increases immune cell activation, enhances effector T cell and NK cell activity, suppresses Treg activity, and improves cancer treatment outcomes by increasing IL-2Rβ binding affinity and reducing CD25 binding, leading to enhanced tumor targeting and therapeutic benefits.
Implementation Method 1
IL-2 muteins having a greater binding capacity for IL-2Rβ as compared to wild-type human IL-2
Data Source
AI summary
Human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor as compared to wild-type IL-2 for use in combination therapies with anti-PD-1 antibodies for the treatment of cancer. Also provided are pharmaceutical compositions that include such anti-PD-1 antibodies and the disclosed IL-2 muteins.